Burosumab for X-linked hypophosphatemia in children and adolescents: Opinion based on early experience in seven European countries

Burosumab for X-linked hypophosphatemia in children and adolescents: Opinion based on early experience in seven European countries

Given the relatively recent introduction of burosumab in the management of X-linked hypophosphatemia (XLH), there is limited real-world data to guide its use in clinical practice. As a group of European physicians experienced with burosumab treatment in clinical practice, we convened with the object...

Full description

Bibliographic Details
Main Authors: M. Zulf Mughal, Giampiero I. Baroncelli, Carmen de Lucas-Collantes, Agnès Linglart, Andrea Magnolato, Adalbert Raimann, Fernando Santos, Dirk Schnabel, Nick Shaw, Ola Nilsson
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-01-01
Series:Frontiers in Endocrinology
Subjects:
XLH
rickets
burosumab
children
adolescents
growth plate closure
Online Access:https://www.frontiersin.org/articles/10.3389/fendo.2022.1034580/full

Internet

https://www.frontiersin.org/articles/10.3389/fendo.2022.1034580/full

Similar Items